Dementia Australia

Dementia Australia has welcomed the publication of the results of a trial showing that a new drug, donanemab, has been able to slow the progression of symptoms of early Alzheimer’s disease.  Dementia Australia CEO Maree McCabe AM said this drug was an exciting new development and another step forward in expanding the number of treatments for dementia.

“These results provide much needed hope for people who are developing symptoms, have mild cognitive impairment or who are in the early stages of Alzheimer’s disease,” Ms McCabe said.